Sartorius Stedim: lowers targets for 2024

(CercleFinance.com) - Sartorius Stedim Biotech has lowered its targets for 2024 on its H1 publication, now forecasting a recurring EBITDA margin of 27% to 29% on sales at around the previous year's level.


The life sciences industry continues to present a mixed picture, with no stable positive momentum, the group says, which is deliberately taking a conservative and cautious approach to the outlook for the remainder of the year.

For H1, the supplier to the pharmaceutical industry reported EPS down 59.3% to E1.08, and recurring EBITDA that is down 6.8% to E387.3m, corresponding to a margin that is down 1.5 point at 28.2%.

Sartorius Stedim Biotech posted sales of E1.37bn, down 2% (-3.8% in organic terms), but taking into account advanced destocking by customers, its order intake rose by 10.4% to E1.26bn.


Copyright (c) 2024 CercleFinance.com. All rights reserved.